Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Feb;24(2):e70051.
doi: 10.1111/jocd.70051.

Effectiveness and Tolerability of an Emollient "Plus" Compared to Urea 10% in Patients With Mild-to-Moderate Atopic Dermatitis

Cita Rosita Sigit Prakoeswa  1   2 , Berliana Kurniawati Nur Huda  1   2 , Ditya Indrawati  1   2 , Menul Ayu Umborowati  1   2 , Sylvia Anggraeni  1   2 , Damayanti  1   2 , Dwi Murtiastutik  1   2 , Delphine Kerob  3
Affiliations
Randomized Controlled Trial

Effectiveness and Tolerability of an Emollient "Plus" Compared to Urea 10% in Patients With Mild-to-Moderate Atopic Dermatitis

Cita Rosita Sigit Prakoeswa et al. J Cosmet Dermatol. 2025 Feb.

Abstract

Background: Atopic dermatitis (AD) poses a challenge due to its chronic inflammatory nature. Recent research highlights microbiome dysbiosis as a key contributor. Emollients "plus" are modern moisturizers containing bacterial lysate, improving skin barrier function and reducing Staphylococcus aureus colonization, thus mitigating AD symptoms. Emollient "plus" containing Vitreoscilla filiformis biomass (Aqua Posae filiformis) is efficient in AD, as single adjunct for milder forms or adjunctive to systemic treatments in more severe forms. Standard recommended moisturizers for AD in Indonesia contain urea 10%.

Aims: This trial compared an emollient "plus" (Group A) with urea 10% moisturizer (Group B) in the treatment of mild-to-moderate AD.

Patients/methods: Sixty subjects with mild-to-moderate AD were randomized into Groups A and B (30 subjects/group). Test products were applied twice daily for 12 weeks. Clinical and instrumental endpoints assessed at Weeks 0, 4, 8, and 12 included Severity Scoring of AD (SCORAD), Pruritus Visual Analog Scale (PVAS), Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), Transepidermal Water Loss (TEWL), skin hydration, skin pH, as well as tolerance evaluation.

Results: Significant differences in favor of the emollient "plus" versus urea 10% were observed on TEWL and skin pH values at Weeks 4, 8, and 12, on SCORAD and skin hydration values at Weeks 8 and 12. EASI, DLQI, and PVAS values differed significantly at Week 12 in favor of Group A. Both products were well tolerated.

Conclusions: This emollient "plus" has superior efficacy in improving AD symptoms and skin barrier function compared to urea 10% moisturizer.

Keywords: atopic dermatitis; emollient “plus”; randomized controlled trial; skin barrier function; urea 10% moisturizer.

PubMed Disclaimer

Conflict of interest statement

Delphine Kerob is an employee of La Roche‐Posay Laboratoire Dermatologique. The other authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Clinical progress of subjects from Group A (emollient “plus”) from Baseline to Week 12.
FIGURE 2
FIGURE 2
Clinical progress of subjects from Group B (urea 10%) from Baseline to Week 12.
FIGURE 3
FIGURE 3
Evolution of SCORAD values over time in Groups A and B. formula image Significant difference: p ≤ 0.05, 95% CI.
FIGURE 4
FIGURE 4
Evolution of PVAS values over time in Groups A and B. formula image Significant difference: p ≤ 0.05, 95% CI.
FIGURE 5
FIGURE 5
Evolution of EASI values over time in Groups A and B. formula image Significant difference: p ≤ 0.05, 95% CI.
FIGURE 6
FIGURE 6
Evolution of DLQI values over time in Groups A and B. formula image Significant difference: p ≤ 0.05, 95% CI.
FIGURE 7
FIGURE 7
Evolution of TEWL values over time in Groups A and B. formula image Significant difference: p ≤ 0.05, 95% CI.
FIGURE 8
FIGURE 8
Evolution of skin hydration values over time in Groups A and B. formula image Significant difference: p ≤ 0.05, 95% CI.
FIGURE 9
FIGURE 9
Evolution of skin pH values over time in Groups A and B. formula image Significant difference: p ≤ 0.05, 95% CI.
See this image and copyright information in PMC

References

    1. Kong H. H., Oh J., Deming C., et al., “Temporal Shift in the Skin Microbiome Associated With Disease Flares and Treatment in Children With Atopic Dermatitis,” Genome Research 22, no. 5 (2012): 850–859. - PMC - PubMed
    1. Hammond M., Gamal A., Mukherjee P. K., et al., “Cutaneous Dysbiosis May Amplify Barrier Dysfunction in Patients With Atopic Dermatitis,” Frontiers in Microbiology 13 (2022): 944365, 10.3389/fmicb.2022.944365. - DOI - PMC - PubMed
    1. Garcia‐Jiménez I., Sans‐de San Nicolàs L., Curto‐Barredo L., et al., “Heterogeneous IL‐9 Production by Circulating Skin‐Tropic and Extracutaneous Memory T Cells in Atopic Dermatitis Patients,” International Journal of Molecular Sciences 25 (2024): 8569, 10.3390/ijms25168569. - DOI - PMC - PubMed
    1. Trzeciak M., Zysk W., and Wolańska‐Buzalska D., “Emollients ‘Plus’ With Vitreoscilla filiformis in Monotherapy and Adjunctive Therapy in Skin Diseases in Children,” Dermatology Review 110 (2023): 602–607.
    1. Zelenkova H., Kerob D., Salah S., and Demessant‐Flavigny A., “Impact of Daily Use of Emollient ‘Plus’ on Corticosteroid Consumption in Patients With Atopic Dermatitis: An Open, Randomized Controlled Study,” Journal of the European Academy of Dermatology and Venereology 37 (2023): 27–34. - PubMed

Publication types

MeSH terms

LinkOut - more resources